Monitor FDA's decision on INO-3107's accelerated approval pathway by the October 30, 2026 PDUFA date, as this will be a critical catalyst. The stock is likely to remain under pressure due to the company's cash constraints and dilutive capital raising, with any positive FDA developments potentially providing temporary relief.
Price Chart
Executive Summary
Inovio Pharmaceuticals is conducting a public offering of common stock and accompanying warrants to raise capital, primarily to prepare for a potential commercial launch of its lead candidate INO-3107 for recurrent respiratory papillomatosis. The offering includes immediate dilution for new investors and comes amid significant uncertainty about FDA approval under the accelerated pathway, with the company acknowledging substantial doubt about its ability to continue as a going concern.
Key Facts
- Company is raising capital through a public offering of common stock and warrants
- Proceeds will be used for commercial launch preparation of INO-3107, confirmatory trial, and pipeline development
- FDA has accepted BLA for INO-3107 under accelerated approval but questioned eligibility, creating significant regulatory uncertainty
- Company acknowledges substantial doubt about its ability to continue as a going concern
- New investors will experience immediate dilution as offering price exceeds net tangible book value
- No established trading market for the warrants being offered
Financial Impact
The offering will provide capital to fund operations, but exact amount undisclosed. New investors face immediate dilution as offering price exceeds net tangible book value per share of $0.35
Risk Factors
- FDA may deny accelerated approval for INO-3107
- Company may not have sufficient capital to fund operations
- Significant dilution for new investors in the offering
- Competition from approved therapy PAPZIMEOS
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-138636 |
| Document: 0001193125-26-138636-index-headers.html | 0001193125-26-138636 |
| Document: 0001193125-26-138636-index.html | 0001193125-26-138636 |
| Document: 0001193125-26-138636.txt | 0001193125-26-138636 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 9w ago | 8-K | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.18 (−75.04%) |
Jul 30, 2026 9w ago | 424B5 | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.18 (−75.04%) |
Jul 30, 2026 9w ago | Press Release | $0.6560 $1.26 | ▼ −92.07% | ▼ −88.11% | $1.18 (−80.64%) |
Jul 13, 2026 11w ago | EFFECT | $1.16 $0.7364 | ▲ +36.52% | ▲ +39.70% | $1.18 (−2.16%) |
Jul 2, 2026 13w ago | S-3 | $1.22 $0.6560 | ▲ +46.23% | ▲ +45.81% | $1.18 (+2.87%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.10 $1.19 | ▲ +8.18% | ▲ +6.29% | $1.18 (+7.73%) |
Apr 6, 2026 25w ago | 8-K | $1.13 $1.14 | ▼ −0.89% | ▲ +8.10% | $1.18 (−4.87%) |
Apr 2, 2026 26w ago | 424B5 | $1.13 $1.12 | ▲ +0.89% | ▲ +10.76% | $1.18 (−4.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access